Amneal Pharmaceuticals, Inc. $AMRX Position Decreased by State of Alaska Department of Revenue

State of Alaska Department of Revenue cut its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 38.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,479 shares of the company’s stock after selling 28,866 shares during the period. State of Alaska Department of Revenue’s holdings in Amneal Pharmaceuticals were worth $915,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Fortitude Family Office LLC lifted its position in Amneal Pharmaceuticals by 100.9% during the third quarter. Fortitude Family Office LLC now owns 1,607 shares of the company’s stock worth $32,000 after buying an additional 807 shares in the last quarter. GK Wealth Management LLC purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at $103,000. Balefire LLC purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at $217,000. GAMMA Investing LLC grew its holdings in Amneal Pharmaceuticals by 54.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,605 shares of the company’s stock valued at $32,000 after buying an additional 569 shares in the last quarter. Finally, Congress Asset Management Co. increased its stake in shares of Amneal Pharmaceuticals by 94.7% in the 3rd quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock worth $30,701,000 after acquiring an additional 741,577 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMRX. Weiss Ratings upgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Zacks Research cut shares of Amneal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Oppenheimer started coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 target price on the stock. Barclays boosted their target price on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 17th. Finally, Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the transaction, the executive vice president owned 253,390 shares in the company, valued at $4,436,858.90. The trade was a 36.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Jason Daly sold 210,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the transaction, the executive vice president owned 35,171 shares of the company’s stock, valued at approximately $611,975.40. This trade represents a 85.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 413,016 shares of company stock valued at $7,216,567 in the last 90 days. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Stock Up 1.8%

Shares of AMRX opened at $20.20 on Thursday. The stock has a market capitalization of $6.45 billion, a PE ratio of 23.07, a P/E/G ratio of 2.33 and a beta of 1.22. Amneal Pharmaceuticals, Inc. has a 1 year low of $9.99 and a 1 year high of $21.17. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The company’s 50-day simple moving average is $18.68 and its 200-day simple moving average is $16.36.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The firm had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.95 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.